The largest pharma companies have all set themselves ambitious targets in recent years to improve representation for women and minority communities in their businesses, but are they meeting
Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for
Dupixent's march towards becoming one of the world's top-selling medicines continued at a healthy lick in the second quarter, allowing Sanofi to raise its full-year earnings forecasts.
Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at th
Sanofi has said it will make 30 of its most commonly prescribed medicines available at non-profit prices to 40 lower-income countries, as part of a global health initiative launched by the
One of the main assets of Sanofi's $3.7 billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical hold while a safety signal is investigated.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.